Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results

tax expense

(1)0.61.1(222.0)(7.0)(227.3) 15 Depreciation3. 24 Amortization0. 4 EBITDA (Loss) (11) - 1 Stock-based compensation8. 43 Gain on sale of equity investments(0.9)---(0.9) — Contingent consideration

(2) 11 Material non-recurringConvertible debt exchange

(3)---13.713.7 — Acquisition expenses

(4)--1.8-1.8 — Adjusted EBITDA$
4.8$   16.8$
59.5 $43 - $55 (1)  Includes the release of the Company's income tax valuation allowance during 2010.(2)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   (3)   Represents debt conversion expense associated with the early conversion of a portion our convertible debt in November 2010.(4)   Represents transactions costs associated with the acquisition of ZyStor Therapeutics Inc., during the third quarter of 2010.   Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDAFor the Four Quarters and Fiscal Year 2009(in millions)(unaudited) 2009Three Months EndedYear Ended DecemberNOTESMarch 31June 30September 30December 3131, 2009GAAP Net Income/(Loss)$
(0.5)Interest expense, net1. tax expense0.40.50.9(0.8)1.0Depreciation2. (Loss)(6.8)10.412.08.924.5Stock-based compensation7. on sale of equity investments-(1.6)--(1.6)Material non-recurringUpfront license fees

(1)8.8---8.8Impairment charges

(2)5.9---5.9Adjusted EBITDA$
5.7$   17.8$
72.1(1)  Represents upfront license payments related to our collaboration agreement with La Jolla Pharmaceutical Company in the first quarter of 2009.   (2)  Includes impairment losses on investments in Summit plc. and La Jolla Pharmaceutical Company recognized during the first quarter

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- An intensive effort to sterilize ... animal shelter in Florida and euthanized, a new study reveals. ... to slow their intake into animal control," Dr. Julie Levy, ... College of Veterinary Medicine, said in a university news release. ... making a big impact," she explained, "so we wanted to ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
(Date:8/22/2014)... again attained the distinguished Magnet hospital designation by ... Program. Considered the gold standard for nursing excellence, ... and professionalism. It is the top international credential ... redesignate Newport Hospital was based on the hospital,s ... practice. , "It is a privilege for us ...
(Date:8/22/2014)... (HealthDay News) -- People who use reduced-nicotine cigarettes don,t ... of nicotine, according to a new study. This ... smokers, the researchers say. The month-long study included ... regular cigarettes with nicotine emission levels of 1.2 milligrams ... to reduced-nicotine cigarettes for the next three weeks. ...
Breaking Medicine News(10 mins):Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Neutering Project Curbed Feral Cat Population 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... chief Commissioner Lester Crawford prevented two senior officials// from deciding ... which is a 'morning after' pill. ,These statements ... for Reproductive Rights. Dr. Steven Galson, director of the FDA's ... thing of approving the action to sell Plan B as ...
... The Schizophrenia Fellowship was announced by the greater Southern Area ... family who are unable to support// patients affected with the ... family sensitive mental health program. It would receive about $2 ... Dr Murray Wright, a director of clinical operations mental health, ...
... Women's Hospital (RBWH), Sydney struggles with an outbreak of ... were found with a bacterium called carbapenem ... ,To prevent the spread, 12 patients from burns unit ... shifted to Sydney hospital and some to Brisbane's Princess ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... of commonly used cholesterol-lowering drugs, used by patients ... anti-arrhythmic effect. Scientists with the ... committee evaluated about 458 sudden cardiac deaths with ... of Statin therapy. Among these about, 229 patients ...
... who tried just one cigarette are twice as likely as those ... 3 years it was proved true by another study. ... children trying even one cigarette. In a study with 2000 teens, ... 15-year olds have smoked a cigarette. From about 36 London schools ...
Cached Medicine News:
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: